Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nom Nom is a pet health and pet nutrition company focused on fresh, personalized meals, treats, and supplements for dogs and cats. The company develops vet-formulated, portion-personalized diets and delivers them directly to consumers, positioning its offering around preventive health, digestibility, and nutrition science rather than traditional therapeutics. Nom Nom also conducts feeding studies and publishes research to support its products, and it operates its own food preparation and packaging capabilities in Nashville, Tennessee. Founded in 2014 and later acquired by Mars in January 2022, the brand operates within Mars Petcare's Royal Canin division while maintaining its own brand identity. For a healthcare-oriented analyst, Nom Nom is best understood as a commercial-stage pet health and nutrition business rather than a biotech or pharmaceutical developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nom Nom.